OBJECTIVES:: PARADIGM-HF, a clinical trial conducted in heart failure (HF) patients, showed that sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor for treatment of HF with reduced ejection fraction (HFrEF), provided incremental cardiovascular and overall survival benefit. This analysis aims to quantify the number of potential deaths avoided with optimal usage of sacubitril/valsartan in the treatment of HFrEF in Argentina. METHODS:: Data from the Pan American Health Organization was used to quantify the target population and a literature review was conducted to determine the prevalence of HF in Argentina, the proportion of those in NYHA Class II-IV and finally, the proportion of patients with HFrEF. The number needed to treat (NNT) to avoid one death, standardized to 12 months, was derived from the PARADIGM-HF trial. The potential number of deaths prevented or postponed as a result of treatment with sacubitril/valsartan was estimated along with multiple-way sensitivity analysis. The main outcome measure was all-cause mortality. RESULTS:: The prevalence of HF in Argentina was estimated at 1.56% and was applied to determine the number of HF patients. Of those, 75% were classified as NYHA Class II-IV, of which, 75% had reduced ejection fraction. This equated to 189,149 HFrEF patients, with NYHA classification II-IV. The percentage of patients eligible for RAS inhibition (ACEI/ARB) was 91%, yielding 172,126 patients. Finally, the absolute reduction in mortality in PARADIGM-HF was 2.8% over an average follow-up time of 27 months. This translates into a NNT standardized to 12 months of 80.3; thus, optimal usage of sacubitril/valsartan therapy was estimated to prevent 2,144 deaths each year. CONCLUSIONS:: The findings from this analysis suggest that a substantial number of deaths could potentially be prevented by optimal implementation of sacubitril/valsartan therapy. Thus, implementation of sacubitril/valsartan into routine clinical practice is important, and may improve clinical outcomes among HFrEF patients in Argentina.